Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003 vs Placebo in Moderate to Very Severe COPD
NCT02347085Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Feb 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of glycopyrronium and formoterol fumarate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Pearl Therapeutics. Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve 0-24 hours at Day 29. Started Feb 2015; status: completed.
02
Drugs
glycopyrroniumformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02347085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347085.